What Onassis Holdings does

Onassis Holdings Corp. is a New York-based biotech holding company founded in 2024 to commercialize over a decade of academic research into epigenetic reprogramming conducted at the Hebrew University of Jerusalem since 2014. The company operates through its wholly owned subsidiary, Ananda Labs, Inc., which houses the biotech R&D function. Onassis's stated mission is to develop treatments that reverse age-related diseases, rejuvenate appearance, and improve immune system function as preventive medicine. Its go-to-market is sales-led and clinical-development-driven: it plans to bring therapies to market through clinical development rather than direct-to-consumer channels, while also engaging investment banks (Dalmore Group) for a Regulation A+ Mini IPO offering of up to $75 million.

The company's core platform is Rejuvenation-based Placental Epigenetic Reprogramming (RPER), a patented set of factors derived from placental and embryonic genes that modify the epigenetic landscape of cells to reverse aging without altering DNA. The factors are administered via reprogramming-factor RNA encapsulated in lipid membranes or clinical-grade adeno-associated viruses (AAVs). The technology is positioned as safer than Yamanaka-factor approaches because it avoids tumorigenic risk while reportedly achieving up to 50% age reversal in adult skin cells while preserving cellular identity. The science is anchored to Co-Founder and CSO Prof. Yossi Buganim, a pioneer in stem-cell reprogramming.

Onassis's product pipeline includes Skin Fibroblast Rejuvenation (a biopsy, culture, rejuvenate, and reinsert procedure that reportedly restores 40%–50% of youthful cell characteristics), an AMD Treatment delivered via ophthalmologist injection, and an Immune System Rejuvenation preventive therapy. Future programs include Hair Loss Reversal, White Hair Reversal, and an at-home Topical Cream formulation. Revenue is expected to come from one-time therapeutic procedures administered in clinical settings and, potentially, from licensing partnerships with biotech, lifestyle, and cosmetic companies. As of the available data, Onassis is pre-revenue with no commercially launched products, no disclosed pricing, and no named customers; the planned Mini IPO is intended to fund development rather than reflect existing scale.

Name

Onassis Holdings

Legal name

Onassis Holdings Corp.

Website

https://onassis-holdings.com

Company type

Private

Founded year

2024

Operating status

Operating

Short description

Onassis Holdings is a New York-based biotech holding company developing epigenetic reprogramming therapies for age-related conditions, operating through subsidiary Ananda Labs and targeting individuals and healthcare/cosmetic partners.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Biotech

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Ophthalmic Regeneration (cornea/retina) (HLAAAGAK), Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL), Medical Wellness & Longevity (Health Screening, Biohacking, Anti-aging Programs) (THAJAHAI)

Keywords

• Epigenetic reprogramming
• Anti-aging therapies
• Cellular rejuvenation
• Biotech therapeutics
• Regenerative medicine

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Therapeutic Treatments: Revenue expected from selling cellular rejuvenation therapies for age-related conditions including skin rejuvenation treatments, AMD eye treatments, and immune system rejuvenation procedures.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Onassis Holdings is a New York-based biotech holding company developing anti-aging treatments through epigenetic reprogramming using patented placental stem cell factors. Operating through subsidiary Ananda Labs, the company is building a pipeline of therapeutic products for skin rejuvenation, age-related macular degeneration (AMD), and immune system rejuvenation. The proprietary Rejuvenation-based Placental Epigenetic Reprogramming (RPER) technology uses placental and embryonic factors to reverse cellular aging while preserving cellular identity.

Product overview

Onassis Holdings is a New York-based biotech holding company focused on developing anti-aging treatments through epigenetic reprogramming. The core offering is the Rejuvenation-based Placental Epigenetic Reprogramming (RPER) technology platform, which uses patented placental and embryonic factors to reverse cellular aging. The company operates through Ananda Labs and is developing a pipeline of therapeutic products including Skin Fibroblast Rejuvenation (the most advanced program), AMD Treatment, Immune System Rejuvenation, and future products for Hair Loss Reversal and White Hair Reversal. The company also plans to develop a topical cream for at-home skin rejuvenation applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Skin Fibroblast Rejuvenation
• Age-Related Macular Degeneration (AMD) Treatment
• Immune System Rejuvenation

Quantifiable outcome

• Up to 50% age reversal achieved in adult skin cells while preserving their identity and function
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Paz Itzhaki-WeinbergerminorOthers · 5 November 2025Paz Itzhaki-Weinberger, Esq. appointed to Advisory Board to oversee international law, trade, and cross-border corporate affairs. Has experience at Microsoft and as CEO of IWC Limited.
• Hebrew University of JerusalemcoreStrategic or Co-development Partner10 years of research collaboration with Prof. Yossi Buganim's lab at Hebrew University, which developed the proprietary patented factors for cellular rejuvenation technology.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Turn Biotechnologies: Turn Bio is developing an mRNA-based epigenetic reprogramming platform (TRN-1) targeting age-related diseases including skin aging and ophthalmology indications. Directly comparable in both modality (non-Yamanaka reprogramming) and target indications such as skin rejuvenation and AMD.
• Altos Labs: Altos Labs is the leading cellular-rejuvenation company, founded in 2022 with ~$3B in committed capital, pursuing partial reprogramming to reverse cellular aging. Directly comparable to Onassis in core thesis (epigenetic reprogramming to reverse age), though much further capitalized and broader in scope.
• Life Biosciences: Life Biosciences is a longevity biotech built around partial reprogramming and other cellular-rejuvenation mechanisms to treat age-related blindness and other diseases. Direct peer on mechanism (partial reprogramming) and on the AMD indication, with similar pre-clinical/early-clinical stage.

Emerging players

• Tissium: Tissium develops biopolymers and tissue adhesives for tissue repair and skin/wound healing applications. Comparable as an emerging player in regenerative tissue-repair technologies that overlap with Onassis's skin regeneration and wound healing indications.
• Insilico Medicine: Insilico Medicine combines AI-driven drug discovery with longevity research, including epigenetic-age programs and age-related disease pipelines. Comparable as an emerging player tackling aging-related biology through novel platforms, overlapping thematically though distinct in core modality (AI-driven small molecules vs. placental-factor reprogramming).
• NewLimit: NewLimit is a Sam Altman-backed epigenetic-reprogramming biotech developing partial reprogramming therapies to extend human healthspan. Directly competes on the core epigenetic reprogramming thesis with capital focus on liver and immune cell rejuvenation.
• Rejuvenate Bio: Rejuvenate Bio (a spinout from George Church's lab) develops gene-therapy-based cellular reprogramming for age-related diseases in both humans and companion animals. Emerging peer using partial reprogramming in a similar indication set, comparable in modality despite smaller scale.
• BioViva Science: BioViva is a longevity biotech focused on telomere and gene therapies for age reversal. Emerging peer in cellular-age-reversal therapeutics; comparable thematically though addresses aging through different molecular mechanisms (telomere biology) than placental reprogramming.

Broad incumbents

• Calico Life Sciences: Calico is Alphabet-backed and pursues a broad portfolio of aging biology research including cellular senescence and reprogramming. An incumbent in cellular aging R&D with vastly greater resources, comparable as the dominant well-funded platform developing therapies that target mechanisms of aging.
• Unity Biotechnology: Unity Biotechnology is a public clinical-stage biotech developing senolytic therapies for age-related diseases including ophthalmology (e.g., AMD). A broader-aging incumbent with overlap in the AMD indication and a senescent-cell-clearance approach to age-related disease rather than reprogramming.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Onassis Holdings